维多珠单抗(抗α4β7整合素)治疗对溃疡性结肠炎患者组织学愈合及黏膜基因表达的影响
研究纳入41例溃疡性结肠炎患者,评估维多珠单抗治疗后第6/12/52周的组织学变化与基因表达。内镜愈合者中55%同时达到组织学愈合,第52周效果最大。组织学愈合者仍存在残留组织学改变和基因表达失调,提示需维持治疗控制肠道炎症。
要点
- 维多珠单抗治疗第6/12/52周时,内镜愈合(Mayo内镜子评分0-1)患者中55%同时达到组织学愈合(Geboes分级0-1)。
- 维多珠单抗仅在第52周恢复内镜愈合患者多种炎症基因的表达,第6/12周未恢复。
- 即使达到组织学愈合,仍可见残留组织学改变(如结构紊乱、单核细胞浸润增加)和基因表达失调,第52周时较少。
核心结论
- 维多珠单抗诱导内镜愈合患者中超过50%达到组织学愈合,第52周效果最大。
- 维多珠单抗在第52周部分恢复内镜愈合患者结肠免疫相关基因的表达。
- 即使组织学愈合者仍存在持续的组织学和基因表达失调,提示需要维持治疗控制肠道炎症。
研究设计与样本
- 研究纳入来自GEMINI I和LTS研究的41例溃疡性结肠炎患者。
- 在维多珠单抗治疗前及治疗后三个时间点(第6/12/52周)采集结肠活检。
- 采用Geboes指数对活检进行组织学评分,并与Mayo内镜子评分进行相关性分析。
- 使用Affymetrix基因芯片分析基因表达。
主要发现
- 在研究的各时间点,维多珠单抗治疗达到内镜愈合(Mayo内镜子评分0-1)的患者中55%同时达到组织学愈合(Geboes分级0-1)。
- 多数组织学愈合者仍可见残留组织学改变(如结构紊乱和单核细胞浸润增加),但第52周时较少。
- 维多珠单抗仅在第52周恢复内镜愈合患者多种炎症基因的表达,第6/12周未恢复。
- 与对照组相比,维多珠单抗组织学愈合者在第6/12/52周时多种基因表达仍失调。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Lymphocyte recruitment to the inflamed gut is increased in UC. Inhibition of this cell trafficking by vedolizumab (VDZ) was successful in inducing and maintaining remission and in induction of endoscopic mucosal healing. There are no data on histological healing with VDZ. We studied histological changes following VDZ therapy and compared gene expression in patients with UC before and after therapy. DESIGN: Forty-one patients with UC from GEMINI I and LTS were studied before and at three time points (weeks 6/12/52) following VDZ therapy. Colonic biopsies were scored using the Geboes index and correlated with Mayo endoscopic subscore. Gene expression was analysed using Affymetrix gene arrays. RESULTS: Fifty-five per cent of patients achieving endoscopic healing (= Mayo endoscopic subscore 0-1) with VDZ at the studied time points also had histological healing (= Geboes grade 0-1). In most healers, some residual histological changes (eg, disturbed architecture and increased mononuclear cell infiltrate) were still observed, although this was less at week 52. VDZ restored expression of many inflammatory genes in patients with endoscopic healing only at week 52 and not before. In VDZ healers, the expression of many genes remained dysregulated at weeks 6/12/52 compared with controls. CONCLUSIONS: VDZ induces histological healing in >50% of patients with endoscopic healing, with maximal effect at week 52. VDZ also restored, although incompletely, the colonic expression of many immune-related genes in patients with UC achieving endoscopic healing at week 52. However, persistent histological and gene dysregulations did remain even in healers, suggesting that maintenance therapy will be necessary to control the intestinal inflammation. TRIAL REGISTRATION NUMBERS: NCT00783718 and NCT00790933; post-results.
引用
- Arijs I, De Hertogh G, Lemmens B, et al. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2016. PMID: 27802155. doi:10.1136/gutjnl-2016-312293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。